1. Home
  2. CODA vs TLSA Comparison

CODA vs TLSA Comparison

Compare CODA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$9.55

Market Cap

134.4M

Sector

Industrials

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.30

Market Cap

155.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CODA
TLSA
Founded
1994
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.4M
155.3M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
CODA
TLSA
Price
$9.55
$1.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
216.7K
179.7K
Earning Date
06-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
15.62
N/A
EPS
0.23
N/A
Revenue
$20,316,161.00
N/A
Revenue This Year
$18.28
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
$41.83
N/A
Revenue Growth
4.98
N/A
52 Week Low
$7.01
$1.04
52 Week High
$18.00
$2.60

Technical Indicators

Market Signals
Indicator
CODA
TLSA
Relative Strength Index (RSI) 38.57 56.52
Support Level $8.86 $1.26
Resistance Level $10.14 $1.44
Average True Range (ATR) 0.75 0.09
MACD 0.01 0.02
Stochastic Oscillator 20.06 96.43

Price Performance

Historical Comparison
CODA
TLSA

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: